search
Pharmaceutical Technology
Trends
- 1MSD Starts Phase I Trial Using Cyprumed Oral Delivery Technology▼Cyprumed‘s Oral Delivery Technology Advances to Clinical Stage as MSD Initiates Phase I Trial
Cyprumed's oral delivery technology has advanced to the clinical stage, with MSD initiating a Phase I trial to test it. The development marks the first time the platform has moved from preclinical work into human testing, a key milestone for companies working on oral delivery of drugs that are otherwise given by injection. It highlights continued industry interest in alternatives to injectable biologics.
- 2
China is rapidly becoming a major power in health technology, driven by advances in AI healthcare applications, biotech, and drug development. Discussion centers on why this matters globally: Chinese firms are scaling innovations in medical AI and pharmaceuticals at speed, with implications for competition, drug pricing, and who sets standards in healthcare technology worldwide.
- 3Novartis signs up to $7.8 billion mRNA deal with China's Abogen▼Novartis strikes up to $7.8 billion mRNA deal with China's Abogen
Swiss drugmaker Novartis has agreed to a licensing deal worth up to $7.8 billion with China's Abogen Biosciences to develop mRNA-based therapies. The agreement gives Novartis access to Abogen's mRNA technology, highlighting growing Western pharmaceutical interest in Chinese biotech assets and keeping momentum behind mRNA platforms beyond vaccines.
- 4
Pharmaceutical Technology has published a magazine edition titled 'Keep it cool'. No further details about its contents are available, and there is no indication yet of what specific topic, product or debate the edition addresses beyond the cooling theme suggested by its title.
- 5
Life science companies are increasingly adopting digital technologies across research, development and operations, according to industry reporting. The shift reflects growing use of data tools, automation and connected systems to speed up drug discovery, improve clinical trials and cut costs. Industry watchers say the trend signals a broader digital transformation now taking hold across the pharmaceutical and biotechnology sectors.
- 6Novartis signs $7.8 billion mRNA deal with China's Abogen●Novartis strikes about $7.8 billion mRNA deal with China's Abogen
Swiss drugmaker Novartis has agreed a deal worth about $7.8 billion with China's Abogen Biosciences, according to Reuters. The agreement centres on mRNA technology, marking a significant move by Novartis into the field and a landmark licensing arrangement for a Chinese biotech firm with a major Western pharmaceutical partner.
- 7Waters Corporation stock draws investor attention▼Waters Corporation (WAT) stock price, news, quote and history
Waters Corporation (WAT), the US laboratory instrument and analytical technology maker, is seeing its stock price, quote and trading history tracked by investors. The company, listed on the New York Stock Exchange, is a key supplier to the pharmaceutical and industrial testing sectors, making its share performance a regular focus for market watchers and finance news readers.
- 8AAPS PharmSci 360 Brings New Insights for Pharma Scientists▼AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
The AAPS PharmSci 360 conference is presenting new research and perspectives for scientists working across the pharmaceutical industry. Coverage highlights fresh insights on drug discovery and development shared at the event, which gathers industry professionals to discuss scientific advances, regulatory topics, and emerging technologies shaping the pharma field.
- 9AllyGPO Wins Stevie Award for Pharma Technology Excellence▼AllyGPO Wins Stevie Award for Technology Excellence in Pharmaceuticals and Biotechnology
AllyGPO has won a Stevie Award for Technology Excellence in the Pharmaceuticals and Biotechnology category. The recognition honours the company's technology work serving the healthcare group purchasing sector. The announcement was made via press release, and details on the specific product or project recognised were not provided.